Welcome back to Endpoints Weekly. Grab a cup of Saturday morning coffee and let’s dive straight into the news — it was a busy week!
GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer.
Eli Lilly shares first human trial results for LOXO-435, a selective FGFR3 inhibitor for bladder cancer, showing 41% response ...
The Trump administration’s effort to remake the federal workforce swept through US healthcare agencies on Friday, with wide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results